The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer.
 
Samir Zaidi
No Relationships to Disclose
 
Joseph Minhow Chan
No Relationships to Disclose
 
Jillian Love
No Relationships to Disclose
 
Jimmy Zhao
Employment - AstraZeneca
Stock and Other Ownership Interests - Intellia Therapeutics; Leap Therapeutics; Mirati Therapeutics; PDS Biotechnology
 
Manu Setty
No Relationships to Disclose
 
Kayla Lawrence
No Relationships to Disclose
 
Anuradha Gopalan
No Relationships to Disclose
 
David Goodrich
No Relationships to Disclose
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; Exelixis; ITM Isotope Technologies Munich; Lantheus Medical Imaging; NCCN; Pfizer
Research Funding - Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis
 
Yu Chen
Stock and Other Ownership Interests - ORIC Pharmaceuticals
Honoraria - Merck
Patents, Royalties, Other Intellectual Property - invention related to glucocorticoid inhibitors for treatment of prostate cancer (SK2013-045),; invention related to glucocorticoid inhibitors for treatment of prostate cancer (SK2013-045),
 
Wouter Karthaus
No Relationships to Disclose
 
Dana Pe'er
No Relationships to Disclose
 
Charles L. Sawyers
Leadership - Novartis
Stock and Other Ownership Interests - Agios; Arsenal Capital; BeiGene; Blueprint Medicines; Foghorn Therapeutics; KSQ Therapeutics; Novartis; ORIC Pharmaceuticals; Petra Pharma; PMV Pharma
Consulting or Advisory Role - Agios; ArsenalBio; BeiGene; Blueprint Medicines; Foghorn Therapeutics; Housey Pharma; KSQ Therapeutics; Novartis; ORIC Pharmaceuticals; Petra Pharma; PMV Pharma
Patents, Royalties, Other Intellectual Property - Apalutamide; Xtandi